NOTUS: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 Inflammation.

The primary objective of this study is the evaluation of the efficacy, safety, and tolerability of dupilumab over one year in patients with moderate-to-severe COPD with Type 2 inflammation. Efficacy will be assessed on multiple COPD domains, including lung function, prevention of moderate and severe exacerbations, and symptom control.